Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 7,061 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Recruiting Not applicable Interventional

Opioid Dispensing Device for Post-Operative Pain in Cancer Patients

NCT05585788
View directory record Official record
Conditions
Opioid Use, Breast Cancer
Interventions
Addinex Device (ADX-27)
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 27, 2026, 2:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab, Tucatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
10
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 27, 2026, 2:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

NCT05756166
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 27, 2026, 2:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

NCT01273610
View directory record Official record
Conditions
Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
Interventions
Lapatinib, Trastuzumab, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
8
States / cities
Duarte, California • Lancaster, California • Pasadena, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 27, 2026, 2:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

NCT04345913
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Eribulin Mesylate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
43
States / cities
Sacramento, California • Derby, Connecticut • Fairfield, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 27, 2026, 2:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spousal Relationships and Pain in Metastatic Breast Cancer

NCT00386620
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaire, Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 27, 2026, 2:46 PM EDT
Not listed Phase 2 Interventional

A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

NCT00907959
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
BZL101
Drug
Lead sponsor
Bionovo
Industry
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 27, 2026, 2:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

NCT02315196
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
pegylated liposomal doxorubicin hydrochloride, epirubicin hydrochloride, carboplatin, therapeutic conventional surgery, paclitaxel, laboratory biomarker analysis, quality-of-life assessment
Drug · Procedure · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2041
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 27, 2026, 2:46 PM EDT
Completed Not applicable Interventional

Accountability for Cancer Care Through Undoing Racism and Equity

NCT01954641
View directory record Official record
Conditions
Breast Cancer, Lung Cancer
Interventions
ACCURE Navigator, Usual Care by Cancer Center Care Team
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Greensboro, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 27, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

NCT00487786
View directory record Official record
Conditions
Neoplasms
Interventions
OGX-427, Docetaxel
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 27, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

NCT00576654
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Interventions
Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
5
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 27, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer

NCT02165605
View directory record Official record
Conditions
Breast Cancer
Interventions
HylaCare, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 27, 2026, 2:46 PM EDT
Recruiting No phase listed Observational

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT04075305
View directory record Official record
Conditions
Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
Interventions
Radiation therapy
Radiation
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Houston, Texas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 27, 2026, 2:46 PM EDT
Completed Not applicable Interventional

Effects of Exercise Intervention on Insulin Levels in Breast Cancer Survivors

NCT00153894
View directory record Official record
Conditions
Breast Cancer
Interventions
Strength training, Endurance training
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 27, 2026, 2:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

NCT05000294
View directory record Official record
Conditions
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
Interventions
Atezolizumab, Tivozanib
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 27, 2026, 2:46 PM EDT
Terminated Phase 1Phase 2 Interventional

Vaccine Treatment for Advanced Breast Cancer

NCT00090480
View directory record Official record
Conditions
Breast Cancer
Interventions
HyperAcute - Breast cancer vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 27, 2026, 2:46 PM EDT
Completed No phase listed Observational Results available

Impact of Radiation Therapy on Breast Conservation in DCIS

NCT02248662
View directory record Official record
Conditions
DCIS
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older · Female only
Enrollment
3,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Hanover, New Hampshire • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 27, 2026, 2:46 PM EDT
Active, not recruiting Phase 2 Interventional

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

NCT03546686
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery, Ipilimumab, Nivolumab
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Columbus, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 27, 2026, 2:46 PM EDT
Recruiting Phase 2 Interventional

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

NCT07402473
View directory record Official record
Conditions
HER2-positive Early-stage Breast Cancer
Interventions
Trastuzumab, Pertuzumab, Docetaxel, Carboplatin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Long Branch, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 27, 2026, 2:46 PM EDT
Completed Not applicable Interventional

A Comparison of the 15 and 30 Acquisition Angle Breast Tomosynthesis Mammography for Breast Abnormalities

NCT00990483
View directory record Official record
Conditions
Breast Cancer
Interventions
3D mammograpgy system
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
40 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 27, 2026, 2:46 PM EDT
Completed Early Phase 1 Interventional

Intraoperative Imaging of Breast Cancer With Indocyanine Green

NCT01796041
View directory record Official record
Conditions
Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Ductal Carcinoma
Interventions
Indocyanine Green
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 27, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

NCT01482156
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
Interventions
RAD001 + BEZ235
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Fayetteville, Arkansas • St Louis, Missouri • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 27, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

NCT03435380
View directory record Official record
Conditions
Breast Neoplasms, Early Detection of Cancer
Interventions
Patient activation, Primary care physician activation, Control
Behavioral
Lead sponsor
Duke University
Other
Eligibility
25 Years and older · Female only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
New York, New York • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 27, 2026, 2:46 PM EDT
Recruiting Phase 2 Interventional

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

NCT04683679
View directory record Official record
Conditions
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions
Pembrolizumab, Olaparib, Radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 27, 2026, 2:46 PM EDT